Lycium barbarum Glycopeptide Inhibits Colorectal Cancer Cell Proliferation via Activating p53/p21 Pathway and Inducing Cellular Senescence
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157091 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Meng Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Integrative Medicine, College of Integrative Medicine, Fujian Key Laboratory of Integrative Medicine on Geriatric, Fujian University of Tr…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cellular Senescence, Tumor Suppressor Protein p53, Lycium. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Science and Technology Innovation Talent Cultivation Program of FJTCM, Scientific Research Foundation for the High-level Talents, Fujian University of Traditional Chinese Medicine.
Abstract (Originalsprache)
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Its sustained proliferative signaling poses a major challenge for effective therapeutic intervention. Since CRC originates from aberrantly proliferating crypt cells, limiting proliferation or inducing senescence may offer a promising treatment approach. Lycium barbarum glycopeptide (LbGP), a traditional Chinese medicine component, is known for its immunomodulatory and other beneficial effects. This study aims to examine the anti-tumor effects of LbGP in CRC as well as its underlying mechanisms of action. We used CT26 CRC cells to investigate the effects of LbGP on tumor proliferation both in vitro and in an allograft mouse model. LbGP treatment significantly inhibited CT26 cell proliferation in vitro and suppressed tumor growth in CT26-implanted mice. Furthermore, LbGP treatment significantly upregulated p53/p21 levels both in vitro and in vivo, leading to CT26 cell cycle arrest in the S phase and the induction of tumor cell senescence. These findings demonstrate that LbGP effectively induces CRC cell cycle arrest and senescence via the p53/p21 pathway and may serve as a promising candidate for CRC adjuvant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Academy of Integrative Medicine, College of Integrative Medicine, Fujian Key Laboratory of Integrative Medicine on Geriatric, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
ORCID-Profile: Meng Yuan, Dan-Ni Ren
Förderung
- Youth Science and Technology Innovation Talent Cultivation Program of FJTCM
- Scientific Research Foundation for the High-level Talents, Fujian University of Traditional Chinese Medicine
Zitieren
APA
Yuan, M., Wo, D., Gong, Y., Lin, M., Ma, E., Zhu, W., & Ren, D. N. (2025). Lycium barbarum Glycopeptide Inhibits Colorectal Cancer Cell Proliferation via Activating p53/p21 Pathway and Inducing Cellular Senescence. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157091
Vancouver
Yuan M, Wo D, Gong Y, Lin M, Ma E, Zhu W, et al. Lycium barbarum Glycopeptide Inhibits Colorectal Cancer Cell Proliferation via Activating p53/p21 Pathway and Inducing Cellular Senescence. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157091
BibTeX
@article{Yuan2025,
author = {Yuan, Meng and Wo, Da and Gong, Yuhang and Lin, Ming and Ma, En and Zhu, Weidong and Ren, Dan-Ni},
title = {Lycium barbarum Glycopeptide Inhibits Colorectal Cancer Cell Proliferation via Activating p53/p21 Pathway and Inducing Cellular Senescence},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157091}
}
EUVIMED